Kevin SchmidChief Executive Officer at Common Sensing, Inc.
Mr. Schmid is the Chief Executive Officer at Common Sensing, Inc. Common Sensing is a Cambridge, MA based company that designs and manufactures disposable injector pen dose monitoring and reporting technology. Since November 2015 Mr. Schmid serves as a member of the Board of Directors for Common Sensing, Inc. and has previously held the position of Chief Operating Officer at Common Sensing. Since January 2018 Mr. Schmid serves as a member of the Board of Directors for Sorrel Medical Ltd. Sorrel Medial is an Israel based company that develops wearable, pre-filled cartridge-based drug delivery platform technology.
Mr. Schmid worked at the Stevanato Group as Vice President Drug Delivery Systems from June 2016 through 2017. The Stevanato Group is a provider of innovative packaging and drug delivery solutions for the pharmaceutical industry. Mr. Schmid served as Insulet Corporation's Vice President of Business Development and Advanced Technology from 2011 to 2015. From 2003 to 2011, Mr. Schmid served as Vice President of Manufacturing and Vice President of Operations and Engineering. During his time at Insulet Corporation, he was instrumental in development, industrialization, and commercialization of the Omnipod Diabetes Management System, the Amgen Neulasta On Body Injector, and the Ferring Pharmaceutical LutrePulse System. Mr. Schmid has held various positions at JDS Uniphase Corporation, Bose Corporation, American Cyanamid, and BIC Corporation, in each case in positions relating to advanced product and manufacturing technology. Mr. Schmid earned a Bachelor of Science in Mechanical Engineering from Clarkson University and a Master of Business Administration from Sacred Heart University.